← All trials
NCT00790335
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2009
- Primary completion
- Jan 1, 2017
- Completion date
- Jan 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 692
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Washington University in St. LouisLead sponsor
- McMaster UniversityOverall official - principal investigator
- McMaster UniversityCollaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Boston Scientific CorporationCollaborator
- Harvard UniversityCollaborator
- BSN Medical IncCollaborator
- Mid America Heart InstituteCollaborator
- Society of Interventional Radiology FoundationCollaborator
- GenentechCollaborator
- Harvard UniversityStudy chair
- Washington University in St. LouisOverall official - principal investigator
- MedtronicCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.